GlobeNewsWire
23 Apr 2026, 03:25 UTC · 27w ago
Verdict
Headline takes no side. We score ALT +0.40 — moderately bullish.
+0.40moderately bullish
More positive than 64% of ticker scores this week
Which stocks this story touches
More positive than 64% of ticker scores this week
The company successfully priced an oversubscribed $225 million public offering to fund its Phase 3 clinical trials.
More positive than 45% of ticker scores this week
Barclays is acting as a joint bookrunning manager for the offering, indicating fee-generating business.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 13% of relationship scores this week
[a_to_b] Barclays is acting as a joint bookrunning manager for Altimmune's public offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
−40.1%
Price is moving against the score
$2.08 vs $3.47 close before publication (Apr 22) · not market-adjusted
ALT chart →
